questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Lectines
Galectines
Galectine -3
Galectine -3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Galectine-3
Tests de laboratoire
Galectine-3
Imagerie médicale
Galectine-3
Analyse d'urine
Symptômes
5
Douleur
Maladies inflammatoires
Symptômes cardiaques
Essoufflement
Prévention
5
Prévention
Mode de vie sain
Exercice physique
Galectine-3
Alimentation
Aliments transformés
Traitements
5
Suppléments alimentaires
Régime alimentaire
Maladies cardiovasculaires
Oncologie
Thérapie génique
Galectine-3
Complications
5
Complications cardiovasculaires
Galectine-3
Insuffisance cardiaque
Galectine-3
Maladies neurodégénératives
Galectine-3
Facteurs de risque
5
Stress chronique
Galectine-3
Maladies auto-immunes
Galectine-3
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Galectine -3 : Questions médicales les plus fréquentes",
"headline": "Galectine -3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Galectine -3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-17",
"dateModified": "2025-02-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Galectine -3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Galectines",
"url": "https://questionsmedicales.fr/mesh/D037161",
"about": {
"@type": "MedicalCondition",
"name": "Galectines",
"code": {
"@type": "MedicalCode",
"code": "D037161",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.503.307"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Galectine -3",
"alternateName": "Galectin 3",
"code": {
"@type": "MedicalCode",
"code": "D037502",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Çiğdem Yücel",
"url": "https://questionsmedicales.fr/author/%C3%87i%C4%9Fdem%20Y%C3%BCcel",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, University of Health Science, Ankara City Hospital, Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Aybeniz Civan Kahve",
"url": "https://questionsmedicales.fr/author/Aybeniz%20Civan%20Kahve",
"affiliation": {
"@type": "Organization",
"name": "Gazi University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Işık Batuhan Çakmak",
"url": "https://questionsmedicales.fr/author/I%C5%9F%C4%B1k%20Batuhan%20%C3%87akmak",
"affiliation": {
"@type": "Organization",
"name": "Sungurlu State Hospital, Department of Psychiatry, Corum, Turkey."
}
},
{
"@type": "Person",
"name": "Erol Göka",
"url": "https://questionsmedicales.fr/author/Erol%20G%C3%B6ka",
"affiliation": {
"@type": "Organization",
"name": "University of Health Sciences, Ankara City Hospital, Department of Psychiatry, Ankara, Turkey."
}
},
{
"@type": "Person",
"name": "Massiullah Shafaq-Zadah",
"url": "https://questionsmedicales.fr/author/Massiullah%20Shafaq-Zadah",
"affiliation": {
"@type": "Organization",
"name": "Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Identification of lncRNA expression profiles in pediatric localized scleroderma.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/35980595",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jocd.15318"
}
},
{
"@type": "ScholarlyArticle",
"name": "Connective tissue nevus misdiagnosed as juvenile localized scleroderma.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37848914",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12969-023-00913-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Juvenile localized scleroderma: A single-centre experience from India.",
"datePublished": "2022-12-03",
"url": "https://questionsmedicales.fr/article/36413107",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jdv.18765"
}
},
{
"@type": "ScholarlyArticle",
"name": "Endpoints and outcomes for localized scleroderma/morphea: a scoping literature review.",
"datePublished": "2024-08-21",
"url": "https://questionsmedicales.fr/article/39169409",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12969-024-01014-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Narrow-band reflectance spectrophotometry and infrared thermography for assessment of skin lesions in localized scleroderma.",
"datePublished": "2022-08-17",
"url": "https://questionsmedicales.fr/article/35925826",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jdv.18483"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lectines",
"item": "https://questionsmedicales.fr/mesh/D037102"
},
{
"@type": "ListItem",
"position": 5,
"name": "Galectines",
"item": "https://questionsmedicales.fr/mesh/D037161"
},
{
"@type": "ListItem",
"position": 6,
"name": "Galectine -3",
"item": "https://questionsmedicales.fr/mesh/D037502"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Galectine -3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Galectine -3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Galectine -3",
"description": "Comment mesurer le taux de galectine-3 ?\nQuels tests sont utilisés pour le diagnostic ?\nLa galectine-3 est-elle un biomarqueur ?\nQuels médecins évaluent la galectine-3 ?\nPeut-on détecter la galectine-3 dans l'urine ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Galectine -3",
"description": "Quels symptômes sont liés à la galectine-3 ?\nLa galectine-3 cause-t-elle des douleurs ?\nY a-t-il des symptômes cardiaques associés ?\nLa galectine-3 est-elle liée à la fatigue ?\nQuels signes cliniques sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Galectine -3",
"description": "Comment prévenir l'augmentation de la galectine-3 ?\nL'exercice physique influence-t-il la galectine-3 ?\nY a-t-il des aliments à éviter ?\nLe stress affecte-t-il la galectine-3 ?\nDes suppléments peuvent-ils aider à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Galectine -3",
"description": "Quels traitements ciblent la galectine-3 ?\nLa galectine-3 peut-elle être traitée par des médicaments ?\nY a-t-il des traitements naturels pour la galectine-3 ?\nLes traitements varient-ils selon la maladie ?\nLa thérapie génique peut-elle cibler la galectine-3 ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Galectine -3",
"description": "Quelles complications sont liées à la galectine-3 ?\nLa galectine-3 aggrave-t-elle les maladies ?\nY a-t-il des risques de cancer associés ?\nLa galectine-3 influence-t-elle la fibrose ?\nDes complications neurologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Galectine -3",
"description": "Quels facteurs augmentent la galectine-3 ?\nLe tabagisme influence-t-il la galectine-3 ?\nL'âge est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nY a-t-il un lien avec les maladies auto-immunes ?",
"url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer le taux de galectine-3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le taux de galectine-3 se mesure par un test sanguin spécifique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "La galectine-3 est-elle un biomarqueur ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est considérée comme un biomarqueur pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels médecins évaluent la galectine-3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cardiologues et oncologues évaluent souvent la galectine-3."
}
},
{
"@type": "Question",
"name": "Peut-on détecter la galectine-3 dans l'urine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La galectine-3 est principalement mesurée dans le sang, pas dans l'urine."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à la galectine-3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est associée à des symptômes d'inflammation et de fibrose."
}
},
{
"@type": "Question",
"name": "La galectine-3 cause-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut contribuer à des douleurs liées à des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cardiaques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'essoufflement peuvent être présents."
}
},
{
"@type": "Question",
"name": "La galectine-3 est-elle liée à la fatigue ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être associée à la fatigue dans des conditions inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'œdème et la dyspnée peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'augmentation de la galectine-3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée, peut aider."
}
},
{
"@type": "Question",
"name": "L'exercice physique influence-t-il la galectine-3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire les niveaux de galectine-3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des aliments à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments transformés et riches en sucres peut être bénéfique."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il la galectine-3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter les niveaux de galectine-3."
}
},
{
"@type": "Question",
"name": "Des suppléments peuvent-ils aider à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments, comme les oméga-3, peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent la galectine-3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de galectine-3 sont en développement pour diverses maladies."
}
},
{
"@type": "Question",
"name": "La galectine-3 peut-elle être traitée par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments visent à réduire son activité dans le corps."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour la galectine-3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches diététiques et des suppléments peuvent aider à la réguler."
}
},
{
"@type": "Question",
"name": "Les traitements varient-ils selon la maladie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements dépendent de la maladie associée à la galectine-3."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle cibler la galectine-3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent la thérapie génique pour moduler son expression."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à la galectine-3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est liée à des complications cardiovasculaires et pulmonaires."
}
},
{
"@type": "Question",
"name": "La galectine-3 aggrave-t-elle les maladies ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aggraver des maladies comme l'insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de galectine-3 sont associés à un risque accru de cancer."
}
},
{
"@type": "Question",
"name": "La galectine-3 influence-t-elle la fibrose ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle joue un rôle clé dans le développement de la fibrose tissulaire."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre galectine-3 et maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent la galectine-3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le diabète et l'inflammation chronique augmentent la galectine-3."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la galectine-3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque pour des niveaux élevés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de galectine-3 augmentent souvent avec l'âge."
}
},
{
"@type": "Question",
"name": "Le stress chronique est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des niveaux élevés de galectine-3."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec les maladies auto-immunes ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies auto-immunes peuvent augmenter les niveaux de galectine-3."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 11/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Biochemistry, University of Health Science, Ankara City Hospital, Ankara, Turkey.
Publications dans "Galectine -3" :
3 publications dans cette catégorie
Affiliations :
Gazi University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey.
Publications dans "Galectine -3" :
3 publications dans cette catégorie
Affiliations :
Sungurlu State Hospital, Department of Psychiatry, Corum, Turkey.
Publications dans "Galectine -3" :
3 publications dans cette catégorie
Affiliations :
University of Health Sciences, Ankara City Hospital, Department of Psychiatry, Ankara, Turkey.
Publications dans "Galectine -3" :
3 publications dans cette catégorie
Affiliations :
Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France.
Publications dans "Galectine -3" :
3 publications dans cette catégorie
Affiliations :
Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France.
Publications dans "Galectine -3" :
3 publications dans cette catégorie
Affiliations :
Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France.
Publications dans "Galectine -3" :
3 publications dans cette catégorie
Affiliations :
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611.
Publications dans "Galectine -3" :
3 publications dans cette catégorie
Affiliations :
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611 ghudalla@bme.ufl.edu.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, University of Health Science, Ankara City Hospital, Ankara, Turkey. rabianazik@gmail.com.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Elazığ Psychiatric Hospital, Elazığ, Turkey.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA 32611. ghudalla@bme.ufl.edu.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Institute of Biostructures and Bioimaging, Consiglio Nazionale Delle Ricerche (CNR), 80134 Naples, Italy.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Institute of Biostructures and Bioimaging, Consiglio Nazionale Delle Ricerche (CNR), 80134 Naples, Italy.
Interuniversity Research Centre on Bioactive Peptides (CIRPEB), University of Naples Federico II, 80134 Naples, Italy.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Interuniversity Research Centre on Bioactive Peptides (CIRPEB), University of Naples Federico II, 80134 Naples, Italy.
Center for Life Sciences and Technologies (CESTEV), University of Naples Federico II, 80145 Naples, Italy.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical Sciences, University of Naples Federico II, Via Cinthia 4, 80126 Naples, Italy.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical Sciences, University of Naples Federico II, Via Cinthia 4, 80126 Naples, Italy.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Institute of Crystallography, Consiglio Nazionale Delle Ricerche (CNR), 81100 Caserta, Italy.
Publications dans "Galectine -3" :
2 publications dans cette catégorie
Affiliations :
Institute of Biostructures and Bioimaging, Consiglio Nazionale Delle Ricerche (CNR), 80134 Naples, Italy.
Interuniversity Research Centre on Bioactive Peptides (CIRPEB), University of Naples Federico II, 80134 Naples, Italy.
Publications dans "Galectine -3" :
The role and potential molecular mechanism of inflammatory cells in pediatric localized scleroderma are poorly investigated. In this study, we first investigated the profiling of inflammatory cells in...
Connective tissue nevi (CTN) are congenital hamartomas caused by excessive proliferation of dermis components. In children, CTN can mimic juvenile localized scleroderma (JLS), an immune mediated skin ...
Aim of our study was to describe a series of pediatric patients with CTN misdiagnosed as JLS and the discerning characteristics between the two conditions....
Retrospective analysis of children referred to our Center during the last two decades for JLS who received a final diagnosis of CTN. Clinical, laboratory, histopathological and instrumental data (MRI ...
Seventeen patients with mean age at onset 4.6 years entered the study. All came to our Center with a certain diagnosis of JLS (n = 15) or suspected JLS (n = 2). The indurated skin lesions were flat an...
CTN can be misdiagnosed as JLS and therefore aggressively treated with prolonged and inappropriate immunosuppression. The absence of inflammatory appearance of the skin lesions, normal instrumental an...
Juvenile localized scleroderma (JLS) or morphoea, a rare chronic autoimmune disease predominantly affects skin, subcutaneous tissue and occasionally the adjacent muscle, fascia and bone. We report the...
Patients who were diagnosed to have JLS were enrolled from the Paediatric Dermatology Clinic and the Paediatric Rheumatology Clinic of a tertiary care referral hospital in India. Collected data includ...
We analysed 84 patients with Juvenile localized scleroderma. Median age of disease onset was 5 years, and median age at diagnosis was 8 years. Commonest subtype was linear scleroderma (57 patients, 67...
Early use of systemic corticosteroids along with methotrexate may be more beneficial than methotrexate therapy alone....
Current treatment for localized scleroderma (LS) has been shown to halt disease activity, but little is still known about patient experiences with these treatments, nor is there consensus about optima...
Conduct a scoping review of the literature for the types of outcomes and measures (i.e. clinician-, patient-, and caregiver-reported) utilized in published treatment studies of LS....
Online databases were searched for articles related to the evaluation of treatment efficacy in LS with a special focus on pediatrics....
Of the 168 studies, the most common outcomes used were cutaneous disease activity and damage measured via clinician-reported assessments. The most frequently cited measure was the Localized Scleroderm...
Some studies only vaguely reported the measures utilized, and the review yielded a low number of clinical trials....
In addition to evaluating disease activity with clinician-reported measures, the field could obtain critical knowledge on the patient experience by including high-quality PROMs of symptoms and functio...
Infrared thermography (IRT) is a useful method to detect activity/inflammation in localized scleroderma (LoS); however, inactive skin lesions with a severe degree of dermal and subcutaneous atrophy ma...
The aim of this research was to compare the spectrophotometric results with thermographic examination of LoS lesions....
The lesions were assessed using the Localized Scleroderma Assessment Tool (LoSCAT), Dyspigmentation, Induration, Erythema, and Telangiectasias (DIET) score, NBRS and IRT. The difference in the erythem...
Fifty-five patients with 49 active and 64 inactive LoS lesions were examined. The ΔEI strongly correlated with the erythema (r...
Narrow-band reflectance spectrophotometry may be a complementary method for determining erythema in LoS active lesions, although this technique remains inferior to IRT, because is unable to distinct b...
Localized scleroderma (LS) is an autoimmune disease with both inflammatory and fibrotic components causing an abnormal deposition of collagen in the skin and underlying tissue, often leading to disfig...
Localized scleroderma (LS) is characterized by skin fibrosis, hyperpigmentation and soft tissue atrophy. Fat grafting has been widely used to correct LS deformity....
To investigate the effect of fat grafting on the skin pigmentation of LS lesions....
A prospective self-controlled study was conducted. Skin melanin and erythema indexes were measured by Mexameter® MX18 before and 3 months after surgery. Differences between lesions and contralateral n...
Fourteen frontal linear LS patients participated in the study. Before surgery, the melanin index of the lesions was significantly higher than the contralateral sites (p = 0.023), while the erythema in...
Fat grafting could alleviate skin hyperpigmentation and skin damage of LS lesions while having little effect on skin erythema and disease activity....
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Inst...
Scleroderma is a rare complication in taxanes therapy. Although individual cases of taxanes-induced scleroderma have been reported, the clinical manifestation and treatment outcomes were reviewed and ...
A PubMed literature review on published cases of taxanes-induced scleroderma up until April 2022 was included for analysis....
The search identified 27 patients with adequate information for analysis. Of the 28 patients, including the one presented here, 22 were female. Peripheral edema was the most common symptom in all but ...
Taxanes-induced scleroderma is different from idiopathic scleroderma. Physicians should be aware of this condition in order to provide early diagnosis and apply appropriate management in order to avoi...
Localized scleroderma (LS) is an autoimmune disease characterized by inflammation and fibrosis, leading to severe cutaneous manifestations such as skin hardening, tightness, discoloration, and other t...
To support physical activity among people with systemic sclerosis (SSc [scleroderma]), we sought to determine the prevalence and importance of barriers and the likelihood of using possible facilitator...
We invited 1,707 participants from an international SSc cohort to rate the importance of 20 barriers (14 medical, 4 social or personal, 1 lifestyle, and 1 environmental) and the likelihood of using 91...
Among 721 respondents, 13 barriers were experienced by ≥25% of participants, including 2 barriers (fatigue and Raynaud's phenomenon) rated "important" or "very important" by ≥50% of participants, 7 ba...
Medical-related physical activity barriers were common and considered important. Facilitators considered as most likely to be used involved adapting exercise, taking care of one's body, keeping warm, ...